# A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

> **NCT01708174** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Medulloblastoma

## Interventions

- **DRUG:** LDE225
- **DRUG:** TMZ

## Key facts

- **NCT ID:** NCT01708174
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-06
- **Primary completion:** 2016-10-05
- **Final completion:** 2016-10-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01708174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01708174, "A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01708174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*